Intra-lesional rF-B7.1 [vaccine; ALVAC CEA] versus rF-tricom vaccine in the treatment of metastatic cancer

Trial Profile

Intra-lesional rF-B7.1 [vaccine; ALVAC CEA] versus rF-tricom vaccine in the treatment of metastatic cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs ALVAC CEA (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Actual end date added to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top